---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-24-000003"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:13:57.471173+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xeris expects Q4 cashflow positive, 2023 revenue at high end of $160M-$165M

## Summary
- Total revenue for FY 2023 expected at high end of prior $160M-$165M guidance.
- Ending cash, equivalents & short-term investments >$72M, above $65M-$70M guidance.
- Q4 2023 expected to be cashflow positive; Q4 & FY results on or about March 6, 2024.
- 2024 outlook: revenue growth, flat opex, declining burn, sufficient cash for obligations.

## SEC filing metadata
- accession: 0001867096-24-000003
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000003/0001867096-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000003/xers-20240104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-24-000003
- JSON: https://secwatch.observer/filing/0001867096-24-000003.json
- Plain text: https://secwatch.observer/filing/0001867096-24-000003.txt

## Key facts
- Earnings Releases
  Xeris Biopharma Holdings, Inc. updated its the year ended December 31, 2023 guidance (reaffirmed).
  - Period: the year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: On January 4, 2024, Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release announcing certain preliminary results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000003/0001867096-24-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.